Loading...

Matinas BioPharma Holdings

DB:6LJ
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6LJ
DB
$147M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Matinas BioPharma Holdings has significant price volatility in the past 3 months.
6LJ Share Price and Events
7 Day Returns
-2.9%
DB:6LJ
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
69.6%
DB:6LJ
-10.6%
DE Biotechs
-6.2%
DE Market
6LJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Matinas BioPharma Holdings (6LJ) -2.9% -18.2% 4% 69.6% - -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 6LJ outperformed the Biotechs industry which returned -10.6% over the past year.
  • 6LJ outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
6LJ
Industry
5yr Volatility vs Market
Related Companies

6LJ Value

 Is Matinas BioPharma Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Matinas BioPharma Holdings. This is due to cash flow or dividend data being unavailable. The share price is €0.892.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Matinas BioPharma Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Matinas BioPharma Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6LJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.15
AMEX:MTNB Share Price ** AMEX (2019-04-18) in USD $1.03
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Matinas BioPharma Holdings.

DB:6LJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:MTNB Share Price ÷ EPS (both in USD)

= 1.03 ÷ -0.15

-6.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Matinas BioPharma Holdings is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Matinas BioPharma Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Matinas BioPharma Holdings's expected growth come at a high price?
Raw Data
DB:6LJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
57.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Matinas BioPharma Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Matinas BioPharma Holdings's assets?
Raw Data
DB:6LJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.06
AMEX:MTNB Share Price * AMEX (2019-04-18) in USD $1.03
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:6LJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:MTNB Share Price ÷ Book Value per Share (both in USD)

= 1.03 ÷ 0.06

18.34x

* Primary Listing of Matinas BioPharma Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Matinas BioPharma Holdings is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Matinas BioPharma Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Matinas BioPharma Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6LJ Future Performance

 How is Matinas BioPharma Holdings expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
57.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Matinas BioPharma Holdings expected to grow at an attractive rate?
  • Matinas BioPharma Holdings's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Matinas BioPharma Holdings's earnings growth is expected to exceed the Germany market average.
  • Matinas BioPharma Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6LJ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6LJ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 57.8%
DB:6LJ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 75.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6LJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6LJ Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 130 172 2
2022-12-31 52 68 2
2021-12-31 0 -23 2
2020-12-31 0 -19 2
2019-12-31 0 -16 2
DB:6LJ Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -10 -15
2018-09-30 0 -10 -15
2018-06-30 0 -10 -15
2018-03-31 0 -11 -16
2017-12-31 0 -11 -33
2017-09-30 0 -12 -31
2017-06-30 0 -10 -34
2017-03-31 0 -8 -31
2016-12-31 -6 -12
2016-09-30 0 -5 -12
2016-06-30 0 -6 -8
2016-03-31 0 -7 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Matinas BioPharma Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Matinas BioPharma Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6LJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Matinas BioPharma Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6LJ Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.98 0.98 0.98 1.00
2022-12-31 0.39 0.39 0.39 1.00
2021-12-31 -0.14 -0.14 -0.14 1.00
2020-12-31 -0.13 -0.12 -0.13 2.00
2019-12-31 -0.12 -0.12 -0.12 1.00
DB:6LJ Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.15
2018-09-30 -0.16
2018-06-30 -0.16
2018-03-31 -0.17
2017-12-31 -0.36
2017-09-30 -0.38
2017-06-30 -0.46
2017-03-31 -0.48
2016-12-31 -0.21
2016-09-30 -0.21
2016-06-30 -0.14
2016-03-31 -0.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Matinas BioPharma Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Matinas BioPharma Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Matinas BioPharma Holdings has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6LJ Past Performance

  How has Matinas BioPharma Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Matinas BioPharma Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Matinas BioPharma Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Matinas BioPharma Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Matinas BioPharma Holdings's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Matinas BioPharma Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Matinas BioPharma Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6LJ Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.12 -14.99 7.98
2018-09-30 0.16 -14.87 7.48
2018-06-30 0.21 -15.16 7.35
2018-03-31 0.16 -15.70 7.48
2017-12-31 0.15 -32.84 7.64
2017-09-30 0.10 -30.95 6.28
2017-06-30 0.06 -33.64 5.84
2017-03-31 0.01 -31.14 5.11
2016-12-31 -11.99 4.31
2016-09-30 0.00 -12.11 4.47
2016-06-30 0.06 -8.03 4.81
2016-03-31 0.14 -8.81 4.95
2015-12-31 0.19 -9.14 4.81
2015-09-30 0.19 -10.17 5.04
2015-06-30 0.13 -10.63 5.23
2015-03-31 0.06 -10.65 5.41
2014-12-31 -10.22 5.29
2014-09-30 -8.98 4.97 0.73
2014-06-30 -7.82 4.14 1.47
2014-03-31 -5.74 2.94 1.71
2013-12-31 -3.71 1.95 1.76
2013-09-30 -2.01 0.90 1.11
2013-06-30 -0.56 0.19 0.36
2013-03-31 -0.22 0.10 0.13
2012-12-31 -0.12 0.04 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Matinas BioPharma Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Matinas BioPharma Holdings has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Matinas BioPharma Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Matinas BioPharma Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Matinas BioPharma Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6LJ Health

 How is Matinas BioPharma Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Matinas BioPharma Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Matinas BioPharma Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Matinas BioPharma Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Matinas BioPharma Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 33.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Matinas BioPharma Holdings Company Filings, last reported 3 months ago.

DB:6LJ Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 16.14 0.39 12.45
2018-09-30 10.30 0.53 6.63
2018-06-30 12.53 0.16 8.90
2018-03-31 8.43 0.21 4.26
2017-12-31 10.68 0.26 7.31
2017-09-30 12.78 0.36 9.00
2017-06-30 15.21 0.07 11.27
2017-03-31 18.86 0.07 15.83
2016-12-31 7.15 0.14 4.11
2016-09-30 8.72 0.22 6.22
2016-06-30 3.00 0.03 0.58
2016-03-31 4.22 0.00 1.67
2015-12-31 6.07 0.01 3.23
2015-09-30 6.96 0.03 4.36
2015-06-30 8.63 0.04 6.61
2015-03-31 6.39 0.05 4.62
2014-12-31 2.23 0.06 2.59
2014-09-30 4.75 0.07 5.01
2014-06-30 6.46 0.08 6.65
2014-03-31 8.61 0.09 8.56
2013-12-31 10.47 0.00 10.84
2013-09-30 12.13 0.00 12.57
2013-06-30 0.38 0.00 0.46
2013-03-31 0.34 0.02 0.42
2012-12-31 0.34 0.02 0.42
  • Matinas BioPharma Holdings's level of debt (2.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 2.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Matinas BioPharma Holdings has sufficient cash runway for 1.1 years based on current free cash flow.
  • Matinas BioPharma Holdings has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 21.4% each year.
X
Financial health checks
We assess Matinas BioPharma Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Matinas BioPharma Holdings has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6LJ Dividends

 What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Matinas BioPharma Holdings dividends.
If you bought €2,000 of Matinas BioPharma Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Matinas BioPharma Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Matinas BioPharma Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6LJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6LJ Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Matinas BioPharma Holdings has not reported any payouts.
  • Unable to verify if Matinas BioPharma Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Matinas BioPharma Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Matinas BioPharma Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Matinas BioPharma Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Matinas BioPharma Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Matinas BioPharma Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6LJ Management

 What is the CEO of Matinas BioPharma Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jerry Jabbour
COMPENSATION $1,254,727
AGE 44
TENURE AS CEO 1.1 years
CEO Bio

Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. Mr. Jabbour served as Executive Vice President, Chief Business Officer, General Counsel and Secretary of Matinas BioPharma Holdings, Inc. from October 2013 to March 7, 2016. He Co-Founded Matinas Biopharma, Inc. Mr. Jabbour has extensive experience in the pharmaceutical and healthcare industries, both domestically and internationally. He served as Executive Vice President, General Counsel & Secretary of MediMedia. Prior to MediMedia, he served as the Senior Vice President and Head of Global Legal Affairs for Wockhardt Limited. Prior to that, he served as Commercial Counsel and Assistant Secretary for Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. In his career, he held positions as counsel at Alpharma and in private practice at Lowenstein Sandler, PC. He has been Director of Matinas Biopharma, Inc. since March 16, 2018. He served as a Director of Matinas BioPharma Holdings, Inc. since August 2, 2013 until November 18, 2013. Mr. Jabbour earned his J.D. from Seton Hall University School of Law in Newark, New Jersey and a B.A. in Psychology from Loyola University in Baltimore, Maryland.

CEO Compensation
  • Jerry's compensation has been consistent with company performance over the past year.
  • Jerry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Matinas BioPharma Holdings management team in years:

0.5
Average Tenure
51
Average Age
  • The average tenure for the Matinas BioPharma Holdings management team is less than 2 years, this suggests a new team.
Management Team

Jerry Jabbour

TITLE
Co-Founder
COMPENSATION
$1M
AGE
44
TENURE
1.1 yrs

Raphael Mannino

TITLE
Senior VP & Chief Scientific Officer
COMPENSATION
$295K
AGE
71
TENURE
3.6 yrs

Keith Kucinski

TITLE
Chief Financial Officer
AGE
48
TENURE
0.3 yrs

Theresa Matkovits

TITLE
Chief Development Officer
AGE
51
TENURE
0.5 yrs

Frank Calamusa

TITLE
Executive Director and Head of Manufacturing & Supply Chain
TENURE
0.5 yrs

Terry Ferguson

TITLE
Chief Medical Officer
AGE
64
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Matinas BioPharma Holdings board of directors in years:

2.9
Average Tenure
53.5
Average Age
  • The average tenure for the Matinas BioPharma Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Herb Conrad

TITLE
Chairman of the Board
COMPENSATION
$256K
AGE
85
TENURE
5.8 yrs

Jerry Jabbour

TITLE
Co-Founder
COMPENSATION
$1M
AGE
44
TENURE
1.1 yrs

Pat LePore

TITLE
Vice Chairman of the Board
COMPENSATION
$214K
AGE
63
TENURE
0.6 yrs

Jim Scibetta

TITLE
Director
COMPENSATION
$235K
AGE
53
TENURE
5.4 yrs

Eric Ende

TITLE
Director
COMPENSATION
$232K
AGE
49
TENURE
2 yrs

Adam Stern

TITLE
Director
COMPENSATION
$210K
AGE
54
TENURE
5.8 yrs

Christie Ballantyne

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs

J. Craft

TITLE
Member of Scientific Advisory Board

David Perlin

TITLE
Member of Scientific Advisory Board
TENURE
3.8 yrs

Peter Pappas

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Matinas BioPharma Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Matinas BioPharma Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6LJ News

Simply Wall St News

6LJ Company Info

Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company’s lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Details
Name: Matinas BioPharma Holdings, Inc.
6LJ
Exchange: DB
Founded: 2013
$130,913,140
142,937,626
Website: http://www.matinasbiopharma.com
Address: Matinas BioPharma Holdings, Inc.
1545 Route 206 South,
Suite 302,
Bedminster,
New Jersey, 07921,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX MTNB Common Stock NYSE MKT LLC US USD 17. Jun 2014
DB 6LJ Common Stock Deutsche Boerse AG DE EUR 17. Jun 2014
Number of employees
Current staff
Staff numbers
15
Matinas BioPharma Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:10
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/04/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.